Press release
IoMT (Internet of Medical Things) to drive the Fibromyalgia Antidepressants Market
As per Persistence Market Research’s latest industry analysis, the global fibromyalgia antidepressants market was valued at US$ 440.8 Mn in 2020, and is expected to exhibit a healthy CAGR of 8.1% over the forecast period (2021-2031)
Rising prevalence of fibromyalgia caused due chronic back pain, previously associated spinal injury, trauma, osteoarthritis, road accidents, and musculoskeletal disorders are expected to drive demand for better treatment along with effective medications for fibromyalgia. Thus, demand for improved treatment with fibromyalgia antidepressants is expected to provide a positive impetus to market growth.
Treatment cost with branded drugs is significantly higher, and it is expected to remain high when compared with generic drugs or other off-label drugs. These higher costs will drive demand for generic drugs. The generic versions of these drugs are likely to see high demand in low-income economies or in economies where these products are limited or not available.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32898
Consolidation activities, mergers, and acquisitions have emerged as a key growth strategy among industry leaders. This trend is quite evident in key markets for fibromyalgia antidepressants.
For instance, the recent acquisition of Allergan plc by AbbVie Inc. in May 2020. This acquisition enabled AbbVie to strengthen its presence across key therapy areas, including immunology, hematologic oncology, and neuroscience.
Similarly, in June 2019, Eli Lily received FDA approval for its migraine drug Emgality, for its use in the treatment in management of cluster headaches.
Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com
Company Profiles:
Pfizer, Inc.
Eli Lilly and Company.
AbbVie, Inc
TONIX Pharmaceuticals Holdings Corp
Virios Therapeutics, Inc.
Aptinyx Inc.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/32898
Key Takeaways from Market Study
In terms of drug class, duloxetine HCL drug holds around 57.8% market value share. Growth is primarily attributed as duloxetine HCL mainly used to treat patients with diabetes and long-term chronic pain.
Based on distribution channel, hospitals pharmacies are leading with over 46% market share, as more patients are consulted at hospitals for fibromyalgia.
By region, North America is set dominate the global market with a value share of around 45.8% in 2021. Europe is slated to be the second-largest leading regional market with a value share of around 20.5% in 2021.
“Rising number of cases of fibromyalgia and better availability of fibromyalgia antidepressant medication are expected to drive market growth over the coming years,” says an analyst of Persistence Market Research.
Market Competition
New product launches and approvals, agreements, collaborations, and partnerships have emerged as key growth strategies adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.
In January 2021, Eli Lilly acquired pharmaceutical rights from Aashi Kahei Pharma of its experimental drug in early-stage testing for managing chronic pain.
In October 2020, Eli Lily entered into a collaboration agreement with Daichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody, which has potential use in the treatment of migrane.
In July 2019, FSD BioSciences, Inc. acquired a U.S.-based company Prismic Pharmaceuticals, which is engaged in developing novel therapies for fibromyalgia treatment.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32898
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the fibromyalgia anti-depressants market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.
The research study is based on the drug class (venlafaxine, duloxetine HCL, milnacipran HCL, and others), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online sales), and seven key regions of the world.
Complete Report Details@ https://www.persistencemarketresearch.com/market-research/fibromyalgia-antidepressants-market.asp
Read More Trending "PMR Exclusive Article"-
Immune Repertoire Sequencing Market@ https://www.persistencemarketresearch.com/market-research/immune-repertoire-sequencing-market.asp
Life Science Market@ https://www.persistencemarketresearch.com/market-research/life-science-market.asp
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
About us-
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release IoMT (Internet of Medical Things) to drive the Fibromyalgia Antidepressants Market here
News-ID: 2545474 • Views: …
More Releases from Persistence Market Research
Red Biotechnology Market Set for Strong 10.8% CAGR Through 2032, Says Persistenc …
The global red biotechnology market is forecast to reach a valuation of US$564.3 billion in 2025 and is projected to nearly double to US$1,149.6 billion by 2032, expanding at a CAGR of 10.8% during the forecast period (2025-2032). The market's robust performance is driven by the rising adoption of gene and cell therapies, accelerated biopharmaceutical innovation, and progressive regulatory reforms across key regions.
Growing investments in mRNA, CRISPR, and precision medicine…
Poultry Medicine Market to Hit US$12.6 Billion by 2032, Reports Persistence Mark …
The global antacids market is valued at approximately USD 7.0 billion in 2025 and is projected to reach around USD 10.0 billion by 2032, growing at a compound annual growth rate (CAGR) of about 4.2% during the forecast period. Rising prevalence of gastroesophageal reflux disease (GERD), heartburn, and acid indigestion, driven by changing dietary habits, stress, and obesity, is fueling the demand for antacids. The market continues to expand as…
Spectroscopy IR Detector Market Anticipated to Hit USD 1,370 Million by 2032
Overview of the Spectroscopy IR Detector Market
The global spectroscopy IR detector market has experienced steady growth in recent years, driven by technological advancements and increasing demand across various industries. Valued at US$ 211.0 million in 2024, the market is projected to reach US$ 825.8 million in 2025 and is anticipated to grow further to US$ 1,370 million by 2032, registering a robust CAGR of 7.5%. Rising environmental concerns and the…
Spectrum Analyzer Market Anticipated to Hit USD 2,138.2 Million by 2032
Overview of the Market
The global spectrum analyzer market is poised for steady growth, with its valuation reaching US$ 1,762.4 million in 2025. Driven by increased adoption of wireless communication systems, rising demand for precise signal analysis, and rapid technological advancements in electronics testing, the market is expected to achieve US$ 2,138.2 million by 2032, registering a CAGR of 2.8% during the forecast period. Spectrum analyzers are crucial for testing, designing,…
More Releases for Fibromyalgia
Government Initiatives On Musculoskeletal Health Propel Growth In The Fibromyalg …
The Fibromyalgia Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Fibromyalgia Treatment Market?
The market for the treatment of fibromyalgia has been expanding consistently in past years. At a compound annual growth rate (CAGR) of 3.9%, it is…
SN Clinic's Effective Treatment of Fibromyalgia Symptoms
Image: https://www.globalnewslines.com/uploads/2025/02/1740408683.jpg
SN Clinic Logo
Fibromyalgia can be a debilitating condition, but SN Clinic offers hope through innovative treatments like MLS Laser Therapy and complementary massage therapies. By addressing chronic pain through a holistic approach, patients can experience significant relief and an improved quality of life.
What is Fibromyalgia and What Does Current Data Say?
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Affecting…
Prominent Fibromyalgia Treatment Market Trend for 2025: Market Leaders Focus On …
What Are the Projected Growth and Market Size Trends for the Fibromyalgia Treatment Market?
The Fibromyalgia Treatment market is expected to grow from $2.79 billion in 2024 to $2.9 billion in 2025, at a CAGR of 3.9%. This growth is attributed to the increasing prevalence of fibromyalgia, greater awareness about the condition, government initiatives, and rising disposable incomes.
The fibromyalgia treatment market is projected to see steady growth, reaching $3.45 billion by…
Advancements in Fibromyalgia Treatments Driving Market Expansion
The fibromyalgia treatment market is experiencing a steady upward trajectory, with significant growth expected over the next decade. Estimated at USD 2.77 billion in 2023, the market is projected to reach approximately USD 4.13 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032. This expansion is driven by several key factors, including advances in treatment options, increasing demand for effective therapies, and…
Fibromyalgia - Drug Pipeline Landscape, 2022
Fibromyalgia is a is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues.
Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD.
To know more about Fibromyalgia - Drug Pipeline, visit - https://www.globalinsightservices.com/reports/fibromyalgia-drug-pipeline-landscape-2022/
Fibromyalgia…
Fibromyalgia Treatment Market 2022 | Increased Morbidity of Fibromyalgia Along w …
According to Precision Business Insights (PBI), the latest report, the Fibromyalgia Treatment market is expected to be valued at USD 3,017.9 million in 2022, growing at an 3.8% CAGR from 2022 to 2028. Fibromyalgia treatment market analysis projects that the increased prevalence of fibromyalgia and its related complication compelled the introduction of targeted & precise treatment methods for fibromyalgia. Also, the increase in awareness about fibromyalgia will give the required…
